Who Group 1 Pulmonary Arterial Hypertension Therapeutics
1. Tracleer patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5292740 | ACTELION | Sulfonamides |
Nov, 2015
(10 years ago) | |
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(4 months from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-607) | Aug 07, 2012 |
| New Product(NP) | Sep 05, 2020 |
| New Patient Population(NPP) | Sep 05, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 05, 2024 |
| ODE*(ODE*) | Sep 05, 2024 |
| Orphan Drug Exclusivity(ODE-161) | Sep 05, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 20 November, 2001
Dosage: TABLET; TABLET, FOR SUSPENSION
How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage
TRACLEER family patents
